Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
12 drugs across 1 manufacturer|0 Generic,12 Brand
The Glucose-dependent Insulinotropic Polypeptide Receptor Agonist class contains 12 NDCs from 1 manufacturer (0 generic, 12 brand), at an average NADAC of $532.22 per unit. Every drug, manufacturer, and price in this FDA-defined pharmacologic class is listed below.
Total Drugs
12
0G / 12B
Manufacturers
1
Avg $532.2158/unit
Avg 7d Change
-0.04%
Across 9 drugs with changes
7d Activity
of 12 total drugs
Class Price Trend
Monthly average NADAC price per unit, split by generic and brand
Manufacturer Breakdown
1 manufacturer producing drugs in this therapeutic class
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
MOUNJARO 2.5 MG/0.5 ML PEN tirzepatide | $538.6419 per ML | +0.01% |
MOUNJARO 10 MG/0.5 ML PEN tirzepatide | $538.6335 per ML | +0.01% |
MOUNJARO 7.5 MG/0.5 ML PEN tirzepatide | $538.6129 per ML | 0.00% |
MOUNJARO 5 MG/0.5 ML PEN tirzepatide | $538.5942 per ML | 0.00% |
MOUNJARO 12.5 MG/0.5 ML PEN tirzepatide | $538.4791 per ML | +0.01% |
MOUNJARO 15 MG/0.5 ML PEN tirzepatide | $538.4770 per ML | 0.00% |
ZEPBOUND 2.5 MG/0.5 ML PEN tirzepatide | $526.1137 per ML | -0.03% |
ZEPBOUND 5 MG/0.5 ML PEN tirzepatide | $526.0139 per ML | -0.03% |
ZEPBOUND 7.5 MG/0.5 ML PEN tirzepatide | $525.7787 per ML | -0.06% |
ZEPBOUND 10 MG/0.5 ML PEN tirzepatide | $525.7717 per ML | -0.07% |
ZEPBOUND 12.5 MG/0.5 ML PEN tirzepatide | $525.7711 per ML | -0.04% |
ZEPBOUND 15 MG/0.5 ML PEN tirzepatide | $525.7024 per ML | -0.07% |
Frequently Asked Questions
How many drugs are in the Glucose-dependent Insulinotropic Polypeptide Receptor Agonist class?
The Glucose-dependent Insulinotropic Polypeptide Receptor Agonist class contains 12 NDCs from 1 manufacturer — 0 generic and 12 brand products.
What is the average price of Glucose-dependent Insulinotropic Polypeptide Receptor Agonist drugs?
The average NADAC for the Glucose-dependent Insulinotropic Polypeptide Receptor Agonist class is $532.2158 per unit across 12 NDCs.
Which manufacturers make Glucose-dependent Insulinotropic Polypeptide Receptor Agonist drugs?
1 manufacturer makes drugs in the Glucose-dependent Insulinotropic Polypeptide Receptor Agonist class. Ranked by number of NDCs, the largest are Eli Lilly and Company (12).
How has Glucose-dependent Insulinotropic Polypeptide Receptor Agonist pricing changed recently?
Over the past 7 days, 3 NDCs in this class rose and 6 fell, with a class-wide average change of -0.0%.